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8 ABSTRACT: Tuberculosis (TB) remains a staggering burden on global public health. Novel preventative tools are desperately
9 needed to reach the targets of the WHO post-2015 End-TB Strategy. Peptide or protein-based subunit vaccines offer potential
10 as safe and effective generators of protection, and enhancement of local pulmonary immunity may be achieved by mucosal
11 delivery. We describe the synthesis of a novel subunit vaccine via native chemical ligation. Two immunogenic epitopes,
12 ESAT61−20 and TB10.43−11 from Mycobacterium tuberculosis (Mtb), were covalently conjugated to the TLR2-ligand Pam2Cys to
13 generate a self-adjuvanting lipopeptide vaccine. When administered mucosally to mice, the vaccine enhanced pulmonary
14 immunogenicity, inducing strong Th17 responses in the lungs and multifunctional peripheral T-lymphocytes. Mucosal, but not
15 peripheral vaccination, provided substantial protection against Mtb infection, emphasizing the importance of delivery route for
16 optimal efficacy.
17 ■ INTRODUCTION
18 Tuberculosis (TB) has plagued human populations for a
19 millennia and remains the leading cause of death from an
20 infectious disease. The causative agent, Mycobacterium tuber-
21 culosis (Mtb), has the capacity to infect a healthy host and
22 persist indefinitely without causing apparent disease, providing
23 a reservoir of infection. Of the estimated 2 billion individuals
24 colonized with Mtb, up to 10% will develop active disease in
25 their lifetime.1 In 2017, there were 1.6 million deaths and 10
26 million new cases of TB. Ten percent of these were children,
27 indicating an ongoing active transmission.2 The only available
28 vaccine for TB, Mycobacterium bovis bacille Calmette−Gueŕin
29 (BCG), is efficacious in reducing the risk of disseminated
30 disease in infants, and its widespread use for TB protection is
31 therefore likely to be continued into the future. However, BCG
32 fails to prevent infection or provide long-term protection
33 against the disease, and additionally is not considered suitable
34 for use in immunocompromised individuals.3 There is
35 therefore an urgent need to explore alternative approaches
36 for the prevention of TB, including novel, safe, efficacious, and
37 easily deliverable vaccines for use as boosters or BCG adjuncts.
38 This is of particular importance considering the growing
39 number of drug-resistant TB cases worldwide.4−6
40 Recent clinical trials of peripheral vaccination with H4/IC31
41 or M72/AS01E, Mtb protein-based adjuvanted subunit
42 vaccines that stimulate CD4+ T-lymphocyte responses,
43demonstrated significant protection against new Mtb infection
44and pulmonary TB, respectively.7,8 Formulation of vaccines for
45pulmonary delivery has been explored for other infectious
46diseases9−11 and shows an opportunity to improve the
47immunogenicity and protective efficacy of TB vaccines by
48generating memory T lymphocytes in the lungs that may
49respond early to Mtb exposure.12,13 Pulmonary vaccination has
50additional practical advantages, as it negates the need for sterile
51needles, containment of sharps waste and large numbers of
52clinically trained personnel, lowering cost.12 The viral-vectored
53vaccine, MVA85A, which failed to provide protection from TB
54in clinical studies when given as a peripheral vaccine,14 is now
55being examined as a pulmonary vaccine15 (Identifier:
56NCT01954563), with a supporting preclinical evidence that
57this route provides greater efficacy.16 Additionally, clinical trials
58are underway for an aerosol adenoviral-vectored TB vaccine
59(Ad85A; Identifier: NCT02337270) and aerosolized BCG
60(Identifier: NCT02709278). Safety concerns exist, however,
61regarding the use of live vaccines or viral vectors for pulmonary
62immunization, and repeat use may be limited due to immune
63responses to the viral backbone.17,18 Protein- or peptide-based
64subunit vaccines may provide a safer alternative, can be used in
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65 immunocompromised individuals, and may be better suited for
66 repeat use.
67 While peptide-based vaccines successfully administer the
68 minimal amount of pathogenic material necessary to elicit an
69 immune response, they often suffer from poor immunoge-
70 nicity. Success in vivo is contingent upon co-administration of
71 immune-stimulating adjuvants. It has been shown by us and
72 others that covalent conjugation of adjuvants to peptide
73 vaccines is an effective means of achieving enhanced immune
74 responses compared to admixtures of individual components,
75 as this minimizes the separation of adjuvant and antigen in
76 vivo, potentiating immunogenicity.19−26 When considering
77 vaccines for pulmonary delivery, immune recognition receptors
78 should be selected that may be accessed at the pulmonary
79 mucosa and safely stimulated. Previous work in our laboratory
80 demonstrated the successful use of powdered pulmonary
81 vaccines, consisting of proteins from Mtb noncovalently
82 associated with a TLR2-ligand, as a safe and effective
83 immunization strategy for TB.27 TLR2 agonizts may be
84 particularly suitable for use in the pulmonary environment, as
85 the receptor is expressed on multiple cell types, including both
86 antigen-presenting cell subsets and pulmonary epithelial
87 cells.28−30 Of particular interest, a recent study demonstrated
88 the protective potential of lipopeptide combinations from the
89 Mtb protein antigen ESAT6 (Rv3875).31 We reasoned
90 therefore that covalent conjugation of peptide epitopes from
91 Mtb to a TLR2-ligand would lead to an effective self-
92 adjuvanted vaccine that may be more stable while providing
93 a robust immunological response.
94 ■ RESULTS AND DISCUSSION
95 Toward this end, we designed a self-adjuvanting vaccine
f1 96 candidate 1 (Figure 1) based on the covalent conjugation of
97 the TLR2/TLR6 agonist Pam2Cys via a small flexible
98 triethylene glycol spacer to two antigenic peptides from the
99 Mtb proteins ESAT6 and TB10.4 (Rv0288 or ESX-H). These
100 peptides, ESAT61−20 and TB10.43−11, possess immunodomi-
101 nant CD4+ and CD8+ T-lymphocyte epitopes, respectively, in
102 C57BL/6 mice. Initially, we attempted a linear synthesis of the
103 vaccine construct using Fmoc-strategy solid-phase peptide
104 synthesis (SPPS), but the lipophilicity of Pam2Cys led to
105 difficulties in purifying the target vaccine to homogeneity. We
106 therefore turned to a native chemical ligation strategy for the
107 convergent and chemoselective fusion of peptide fragments to
108 generate larger constructs.32 It was envisaged that a native
109 chemical ligation strategy would permit initial synthesis of a
110 shorter and easily purifiable lipopeptide thioester fragment,
111 which could then be rapidly conjugated to the rest of the
112 vaccine construct. To reduce the number of purification steps,
113 2,2,2-trifluoroethanethiol (TFET) was selected as a thiol
114 additive to promote rapid ligation while enabling in situ radical
115 desulfurization to access the target vaccine 1 (with a native
116alanine residue at ligation junction) in a one-pot manner.33
117With this synthetic strategy in mind, we chose to disconnect
118the vaccine between Phe8 and Ala9 of the ESAT6 epitope
119(Figure 1). This led to two synthetic targets, lipopeptide
120 s1thioester 2, bearing an N-terminal Pam2Cys residue (Scheme
121 s11B), and peptide 3, possessing an N-terminal cysteine in place
122of native Ala9 in the ESAT6 epitope (Scheme 1C).
123Synthesis of lipopeptide thioester 2 was achieved via Fmoc-
124strategy SPPS on Rink amide resin using an on-resin
125thioesterification procedure.34 Initially, we synthesized Fmoc-
126AspPhe-OAll 4 (Scheme 1A). This began by allyl ester
127protection of Boc-Phe-OH (5) to afford 6, followed by Boc
128deprotection and coupling to Fmoc-Asp(OtBu)-OH to afford
129dipeptide 8 in good yield. Deprotection of the side-chain tBu
130ester on the aspartate residue then provided the target
131dipeptide 4. With 4 in hand, it was next loaded via the
132condensation of the side-chain carboxylate of the aspartate
133residue to Rink amide resin (Scheme 1B). The polypeptide
134chain was then elongated using iterative Fmoc-SPPS, with
Figure 1. Self-adjuvanting vaccine candidate 1, covalently conjugated
Pam2Cys as adjuvant and immunodominant T-lymphocyte epitopes
from Mtb, ESAT61−20 and TB10.43−11.
Scheme 1. (A) Synthesis of Dipeptide Building Block 4 from
Boc-Phe-OH; (B) Synthesis of Lipopeptide Thioester
Fragment 2 via Side Chain Anchoring, Fmoc-SPPS and
Subsequent On-Resin Thioesterification; NB: Amino Acids
within Resin-Bound Peptides Possess Standard Side-Chain-
Protecting Groups Used in Fmoc-SPPS; (C) Synthesis of
Peptide Fragment 3 via Fmoc-SPPS
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135 amino acid, triethyleneglycolate, and Pam2Cys couplings
136 effected with N,N′-diisopropylcarbodiimide (DIC) and ethyl
137 (hydroxyimino)cyanoacetate (Oxyma). At this point, the allyl
138 ester-protected C-terminus of the peptide was unmasked by
139 treatment with palladium tetrakis-triphenylphosphine and
140 phenylsilane. Treatment with ethyl 3-mercaptopropionate in
141 t h e p r e s e n c e o f ( b e n z o t r i a z o l e - 1 - y l o x y ) -
142 tripyrrolidinophosphonium hexafluorophosphate (PyBOP)
143 and N,N-diisopropylethylamine at −15 °C35,36 led to the
144 formation of the C-terminal thioester with no detectable
145 epimerization. Cleavage of the peptide thioester using an acidic
146 cocktail comprising trifluoroacetic acid (TFA), triisopropylsi-
147 lane, and water provided the crude lipopeptide thioester, which
148 was purified via reverse-phase high-performance liquid
149 chromatography (HPLC) to afford 2 in 21% yield (over 43
150 steps calculated from the initial resin loading). Peptide 3 was
151 also accessed via Fmoc-strategy SPPS and isolated in 32% yield
152 (over 63 iterative steps based on the initial resin loading)
153 following reverse-phase HPLC (on C18 stationary phase)
154 (Scheme 1C).
155 With the two target fragments in hand, our attention turned
156 to the key ligation−desulfurization assembly of vaccine 1.
157 Native chemical ligation is typically carried out in aqueous
158 phosphate buffer (0.1 M, pH ∼7) containing tris-
159(carboxyethyl)phosphine (TCEP, 50 mM) as a reductant
160and guanidine hydrochloride (Gdn.HCl, 6 M) as a denaturing
161agent. However, lipopeptide thioester 2 was insoluble in this
162buffer system and, as a result, we supplemented the buffer with
163the nonionic surfactant Tween-20 (0.5% v/v) as a solubilizing
164detergent. Specifically, lipopeptide thioester 2 and peptide 3
165were dissolved in this buffer and 2,2,2-trifluoroethanethiol
166(TFET, 2% v/v) was added.33 Pleasingly, within 2 h, the
167reaction proceeded to completion to afford the ligation
168product. Without purification, in situ desulfurization of the
169ligation product was performed through treatment with the
170radical initiator 2,2′-azobis[2-(2-imidazolin-2-yl)propane]-
171dihydrochloride (VA-044) (20 mM) in the presence of
172reduced glutathione (40 mM) and TCEP (250 mM) to
173convert the cysteine to a native alanine residue at the ligation
174junction. HPLC purification using C18 reverse-phase HPLC
175furnished self-adjuvanting TB vaccine candidate 1 in 34% yield
176 s2over two steps (Scheme 2).
177The adjuvant activity of the synthesized conjugate vaccine 1
178was first verified in vitro. Specifically, Pam2Cys binding and
179activation of the TLR2 signaling pathway was assessed in a
180HEK-TLR2-reporter cell line. Conjugate vaccine 1 showed a
181strong activation of TLR2, comparable to stimulation with
182 f2Pam2Cys-SKKKK-PEG(OH) (Figure 2). The in vivo
Scheme 2. (A) Synthesis of Self-Adjuvanting Tuberculosis Vaccine Candidate 1 via One-Pot Native Chemical Ligation and
Desulfurization; (B) Analytical HPLC Chromatogram, (C) electrospray ionization mass spectrometry (ESI-MS), and (D)
matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS Spectrum of Vaccine 1
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183 immunogenicity induced by 1 was assessed in mice; three
184 homologous vaccinations were given 2 weeks apart and
185 responses were assessed 3 weeks after the final vaccination.
186 Mice were immunized at either the pulmonary mucosa via
187 intranasal (i.n.) instillation or peripherally by subcutaneous
188 (s.c.) injection. The use of defined immunodominant peptide
189 epitopes as antigens enabled quantitative and qualitative
190 assessment of the CD4+ and CD8+ T-lymphocyte responses
191 generated both locally and systemically. Lymphocytes from the
192 lungs and spleens of immunized mice were restimulated with
193 ESAT61−20 or TB10.43−11 peptides ex vivo prior to intracellular
194 immunostaining and flow cytometry. Mucosal delivery of 1
195induced substantial populations of ESAT6-specific CD4+ T-
196 f3lymphocytes in the lungs producing IL-17 and TNFα (Figure
197 f33A). The multifunctionality of local T-lymphocytes were also
198increased, such that significant populations of IL-17+ CD4+
199cells were observed that also expressed other key cytokines,
200including IFNγ, IL-2, and TNFα, indicative of a predominantly
201Th17-like phenotype (Figure S1). Notably, there was minimal
202detectable cytokine response in the lungs of mice that were
203vaccinated s.c. (Figures 3A and S1). The profile of cytokine-
204producing ESAT6-specific CD4+ T-lymphocytes in the spleens
205of mucosally immunized mice was similar to that seen in the
206lungs, but additionally with enhanced IL-2 responses (Figures
2073B and S2). A minor population of IL-2- and TNFα-producing
208cells were observed in the spleens of s.c. immunized mice;
209however, no other significant populations were identified
210(Figures 3B and S2). No significant cytokine-producing CD8+
211populations were seen in the lungs of any immunized group in
212response to TB10.43−11 (Figure S3A), but small populations of
213IFNγ- and TNFα-producing CD8+ cells were seen in the
214spleens of s.c. immunized mice (Figure S3B). This may
215indicate that murine leukocytes were not able to efficiently
216process this epitope from 1 appropriately for presentation to
217CD8+ T-lymphocytes. Overall, mucosal delivery of the vaccine
218candidate 1 substantially improved pulmonary immunogenicity
219and preferentially led to a strong Th17-like CD4+ T-
220lymphocyte response.
221Adjuvants for new vaccines should ideally be selected based
222on their ability to induce the type of immune response best
223correlated with protection against the pathogen. In the case of
224Mtb, there is strong evidence that a Th1-type CD4+ T-
225lymphocyte response is required; however, this is not sufficient
Figure 2. Vaccine candidate 1 activates TLR2 signaling in vitro.
Stimulation of IL-8 released from HEK-TLR2 reporter cells by
synthetic conjugate 1 is shown in comparison to stimulation with PBS
(Nil), ESAT61−20 or TB10.43−11 peptides, or Pam2Cys-PEG(OH)
alone (at ∼7 μM). Data are mean ± standard error of the mean
(SEM) (n = 3) and are representative of two independent
experiments.
Figure 3. Mucosal, but not peripheral, delivery of 1 induces a strong antigen-specific pulmonary IL-17 and TNFα responses that are maintained
post-Mtb challenge. Frequency of cytokine-producing CD4+ T-lymphocytes in the (A) lungs and (B) spleen 3 weeks following final immunization
(n = 3) and (C) lungs and (D) spleen 4 weeks post-Mtb challenge (n = 6). Epitope-specific cells were detected by intracellular immunostaining and
flow cytometry after recall with ESAT61−20 (10 μg/mL). Data are mean ± SEM. Statistically significant differences (A, B) to relevant Pam2Cys
control by analysis of variance (ANOVA) with Tukey’s multiple comparison test, and (C, D) to Nil control, by ANOVA with Dunnett’s multiple
comparison test (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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226 for sterilizing immunity.37 Immunization at the pulmonary
227 mucosa tends to drive a Th17-based response to peptide
228 antigens, likely due to the induction of IL-1, IL-6, and TGFβ
229 expression.38,39 TLR2 stimulation, which leads to the
230 production of TNF and IL-6, is critical for the activation of
231 antigen-presenting cells28 and are also inducers of Th17
232 polarization, characterized by IL-17, IL-21, and IL-22
233 production. IL-17 may promote granuloma formation and
234 neutrophil recruitment by inducing the pro-inflammatory
235 cytokines and chemokines G-CSF, IL-6, and IL-8,40,41 as well
236 as recruitment of IFNγ-producing cells to the site of infection
237 by induction of CXCL10 expression.42 This is suggested to be
238 one of the mechanisms by which Th17 cells may promote the
239 immune response to Mtb.43 While the role of vaccine-induced
240 IL-17 in protection against Mtb is controversial,44,45 several
241 studies have indicated the plasticity of vaccine-induced Th17
242 cells in mice, and their capacity to revert after exposure to Mtb
243 to expression of the classical Th1-associated cytokine IFNγ,
244 even after long-term residency as memory cells in the
245 lungs.46,47 It is therefore possible that mucosal immunization
246 with 1, despite inducing primarily strong Th17 responses, may
247 provide a pool of lung resident CD4+ T-lymphocytes that can
248 function as Th1 or Th17 as needed and provide protective
249 responses against the pathogen.12,13
250 Having demonstrated robust pulmonary immunogenicity
251 from mucosal administration of 1, we next tested the self-
252 adjuvanting vaccine candidate in an aerosol Mtb infection.
253 C57BL/6 mice received three homologous immunizations 3
254 weeks apart with i.n. Pam2Cys alone or 1 by i.n. instillation or
255 s.c. injection. A separate group of mice received BCG s.c.,
256 considered the gold-standard comparison in murine models of
257 Mtb challenge.48 After 6 weeks, the mice were challenged by
258 aerosol with Mtb and the postchallenge immune response to
259 the vaccine epitopes were assessed 4 weeks later. Mice
260 immunized i.n. with 1 had maintained significantly upregulated
261 populations of ESAT6-specific CD4+ T-lymphocytes produc-
262 ing IL-17 and TNFα in the lungs, which were not seen in
263 peripherally immunized mice (Figure 3C). The diversity of
264 multifunctional cytokine-producing populations in the lungs of
265 mucosally immunized mice was maintained postchallenge
266(Figure S4). Populations of a similar phenotype were also seen
267in the spleen (Figures 3D and S5), consistent with the
268immunogenicity pre-Mtb challenge. At this postchallenge
269stage, mice immunized s.c. had increased ESAT6-specific
270IFNγ+, IL-2+, and TNFα+ CD4+ T-lymphocyte populations in
271the spleen (Figures 3D and S5). There were minimal vaccine-
272induced responses seen to the TB10.43−11 peptide post-
273challenge, and it is likely that these populations reflect
274responses to the Mtb challenge itself (Figure S6).
275To assess if the T-lymphocyte responses generated by 1
276were functionally beneficial, the Mtb bacterial burden in the
277lungs and spleen were enumerated to determine the protective
278efficacy of the vaccine. We were pleased to observe that when 1
279was delivered mucosally, it provided substantial protection in
280both the lungs and spleen, similar to that provided by BCG
281 f4(Figure 4). Consistent with the immunological data, while
282there was a trend toward protection in the lungs after
283subcutaneous vaccination, this did not reach statistical
284significance in all experiments (Figure 4A) and no protection
285was seen in the spleen (Figure 4B). These data strongly
286support the model that vaccination strategies promoting a
287pulmonary immune response offer more robust protection
288from Mtb. Taken together, this study provides an exciting
289proof of principle data that synthetic self-adjuvanting peptide
290vaccines can provide substantial pulmonary immunogenicity
291and protection against virulent Mtb.
292■ CONCLUSIONS
293In summary, we have successfully produced a synthetic
294lipopeptide conjugate vaccine candidate 1 by one-pot native
295chemical ligation−desulfurization chemistry and assessed the
296delivery by pulmonary or peripheral routes to induce
297protective immune responses to Mtb. Mucosal delivery offered
298increased immunogenicity and protective efficacy. The use of
299this vaccine in humans will depend on future toxicology and
300careful evaluation of the adjuvant Pam2Cys in phase I clinical
301studies. It will be important in future studies to assess whether
302pulmonary vaccination with constructs such as 1 may be used
303to boost the protective efficacy of BCG or improve the long-
304term protective efficacy against Mtb. Pulmonary boosting may
Figure 4. Protective efficacy against Mtb infection was induced by mucosal immunization with 1. Mice (n = 6) were immunized with 1 (10 μg
peptide component), or an equivalent amount of Pam2Cys, three times at two-weekly intervals. Six weeks later, the mice were challenged with
aerosol Mtb H37Rv (100 CFU). Alternatively, the mice received 5 × 105 CFU BCG s.c. 10 weeks before challenge. After 28 days, the bacterial
loads in (A) lungs and (B) spleen were enumerated. Data are mean ± SEM and are representative of two independent experiments. Statistical
significance was determined by ANOVA with Tukey’s multiple comparisons test (*p < 0.05, **p < 0.01, ***p < 0.001).
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305 have the additional benefit of drawing memory T-lymphocytes
306 generated by subcutaneous BCG into the lungs, creating a
307 further reservoir of memory cells that may act quickly to
308 combat future encounter with Mtb. Further, these conjugated
309 lipopeptides provide the means to assess the impact that the
310 type of conjugation between antigen and adjuvant has on
311 immunogenicity and protective efficacy. The ligation technol-
312 ogy employed in this study is applicable to the conjugation of
313 diverse peptide or protein antigens to different adjuvants that
314 stimulate a variety of pattern recognition receptors. Exploring
315 pulmonary administration to enhance efficacy and ease of
316 delivery with a range of different adjuvants and antigens from
317 Mtb may contribute novel constructs to the TB vaccine
318 pipeline and will be the subject of continued work in our
319 laboratories.
320 ■ EXPERIMENTAL SECTION
321 General Methods. Unless otherwise stated, reactions were carried
322 out under an argon atmosphere and at room temperature (rt) (22
323 °C). Reactions carried out at 0 °C employed a bath of water and ice.
324 Anhydrous CH2Cl2 and dimethylformamide (DMF) was obtained
325 using a PureSolv solvent purification system (water < 10 ppm).
326 Reactions were monitored by thin layer chromatography (TLC) on
327 aluminum-backed silica plates (Merck Silica Gel 60 F254). Visual-
328 ization of TLC plates was undertaken with an ultraviolet light at λ =
329 254 nm and staining with solutions of vanillin or phosphomolybdic
330 acid, followed by exposure of the stained plates to heat. Silica gel 60
331 40−63 μm was used for flash column chromatography. NMR
332 spectroscopy was performed in CDCl3 on a Bruker DRX 300 or
333 DRX 400 NMR spectrometer at frequencies of 300 MHz or 400 MHz
334 for 1H NMR and 75 or 100 MHz for 13C NMR, respectively.
335 Chemical shifts are reported in parts per million (ppm) and coupling
336 constants in Hertz (Hz). Residual solvent was used as internal
337 standards (CDCl3: δH = 7.26, δC = 77.16).
13C NMR data are
338 reported as chemical shift values (ppm). Mass spectrometry with
339 electrospray ionization (ESI) was performed on a Shimadzu 2020
340 (ESI) mass spectrometer operating in a positive mode. High-
341 resolution mass spectra were recorded on a Bruker-Daltronics Apex
342 Ultra 7.0T Fourier transform (FTICR) mass spectrometer. MALDI-
343 TOF mass spectrometry was performed on a Bruker Autoflex Speed
344 MALDI-TOF mass spectrometer operating in reflectron mode using a
345 matrix of 10 mg/mL α-cyano-4-hydroxycinnamic acid in water/
346 acetonitrile containing 0.1% TFA (1:1 v/v). Optical rotations were
347 measured on a PerkinElmer 341 polarimeter at a wavelength of 589
348 nm. IR spectra were recorded on a Bruker Alpha FT-IR spectrometer
349 using a diamond ATR unit. The purity of all compounds was >97% as
350 judged by NMR spectroscopy and HPLC.
351 General Procedure for Fmoc-SPPS. Fmoc-SPPS was performed
352 on a Biotage Initiator+ Alstra microwave peptide synthesizer using the
353 following conditions. Amino acid coupling: A solution of Fmoc-
354 protected amino acid (4 equiv), DIC (4 equiv), and Oxyma (4 equiv)
355 in DMF (Labscan, final amino acid concentration 0.1 M) was added
356 to the resin. After 30 min at 50 °C, the resin was washed with DMF
357 (5 × 5 mL). Deprotection: The resin was treated with 20%
358 piperidine/DMF (2 × 3 mL, 3 min) at rt and then washed with
359 DMF (5 × 5 mL). Capping: Ac2O/pyridine (1:9 v/v) was added to
360 the resin (3 mL). After 3 min, the resin was washed with DMF (5 × 5
361 mL).
362 General Procedure for Resin Cleavage. Peptides were cleaved
363 from resin (with concomitant side-chain deprotection) by treatment
364 with an acidic cocktail containing TFA/triisopropylsilane/water
365 (90:5:5 v/v/v) with gentle shaking for 2 h. The cleavage solution
366 was filtered and the resin washed with TFA (2 × 2 mL). The solution
367 was concentrated and then precipitated with cold diethyl ether. The
368 mixture was centrifuged and the supernatant was discarded.
369 Preparative and Semipreparative Reverse-Phase HPLC.
370 HPLC purification was performed using a Waters 600 Multisolvent
371 Delivery System and Waters 500 pump with a Waters 490E
372programmable wavelength detector operating at 214, 230, or 280
373nm. Peptide 3 was purified by preparative HPLC on a Waters Sunfire
374C18 column (5 μm, 19 × 150 mm) at a flow rate of 7 mL min−1
375(solvent A: 0.1% TFA in H2O; solvent B: 0.1% TFA in MeCN).
376Lipopeptides 1 and 2 were purified by semipreparative HPLC on a
377Phenomenex Luna C18(2) column (5 μm, 10 × 250 mm) in a
378column heater at 40 °C and a flow rate of 7 mL min−1 (solvent A:
3790.1% TFA in H2O:MeCN:iPrOH (8:1:1 v/v/v); solvent B: 0.1% TFA
380in MeCN:iPrOH (9:1 v/v)).
381Synthesis of Vaccine 1 via One-Pot Native Chemical
382Ligation Desulfurization. Lipopeptide thioester 2 (2.5 mg, 0.96
383μmol) and peptide 3 (2 equiv, 4.2 mg, 1.92 μmol) were dissolved in
384aqueous phosphate buffer (0.1 M, pH = 7.4, 192 μL, 5 mM with
385respect to thioester 2) containing guanidine hydrochloride (6 M),
386TCEP (50 mM), and Tween-20 (0.5% v/v). The pH of the reaction
387mixture was adjusted with aqueous NaOH (1 M) to pH 7.2. TFET
388(2% v/v) was added and the reaction was incubated at 37 °C for 2 h.
389The reaction was followed by ultraperformance liquid chromatog-
390raphy-tandem mass spectrometry (UPLC-MS). After consumption of
391the thioester (as measured by UPLC-MS analysis, 2 h) the reaction
392was degassed under a stream of argon, and one volume of degassed
393aqueous phosphate buffer containing guanidine hydrochloride (6 M),
394TCEP (500 mM), reduced glutathione (80 mM), and the radical
395initiator VA-044 (40 mM) was added. The reaction was allowed to
396proceed at 37 °C for 8 h, at which time the ligation product bearing
397cysteine at the ligation junction was fully converted to the
398corresponding alanine-containing product (as judged by UPLC-MS
399analysis). Semipreparative HPLC purification (0−60% B over 40 min,
4007 mL min−1, 40 °C, Phenomenex Luna C18(2), 5 μm, 100 Å, 10 ×
401250 mm) followed by lyophilization afforded pure vaccine candidate 1
402as a white solid (1.5 mg, 34% yield). Analytical HPLC: Rt 16.9 min
403symmetry C4 column, 300 Å, 5 μm, 4.6 mm × 250 mm, gradient:
40420−100 B over 25 min (solvent A: H2O + 0.1% TFA, solvent B:
405MeCN + 0.1% TFA); MS calcd: [M + 3H]3+ = 1545.48, [M + 4H]4+
406= 1159.36, [M + 5H]5+ = 927.69; found (ESI+): 1545.95, 1159.65,
407927.85. HRMS calcd for C214H348N47O58S4: [M + H]
+ = 4634.466;
408found (MALDI-TOF): 4634.462.
409Synthesis of Lipopeptide Thioester 2. Rink amide resin (25
410μmol, 0.3 mmol/g loading) was initially washed with CH2Cl2 (5 × 3
411mL) and DMF (5 × 3 mL), followed by Fmoc deprotection with 20%
412piperidine/DMF (2 × 5 min). The resin was washed with DMF (5 ×
4133 mL), CH2Cl2 (5 × 3 mL), and DMF (5 × 3 mL). PyBOP (4 equiv)
414and N-methylmorpholine (NMM) (8 equiv) were added to a solution
415of Fmoc-AspPhe-OAll 4 (4 equiv) in DMF. After 5 min of
416preactivation, the mixture was added to the resin and then shaken
417at rt for 2 h. The resin was filtered, then washed with DMF (5 × 3
418mL), CH2Cl2 (5 × 3 mL), and DMF (5 × 3 mL), capped with Ac2O/
419pyridine (1:9 v/v; 2 × 3 min), and washed with DMF (5 × 3 mL),
420CH2Cl2 (5 × 3 mL), and DMF (5 × 3 mL). The resin-bound H-
421SKKKK-triethyleneglycolate-ESAT6(1−8) peptide was synthesized
422on the side-chain-loaded resin using the general procedure for Fmoc-
423SPPS. For the coupling of Pam2Cys, a solution of Fmoc-Pam2Cys-OH
424(1.2 equiv), DIC (1.2 equiv), and HOAt (1.5 equiv) in DMF was
425added to the resin, and the reaction was shaken at rt for 16 h. The
426resin was next treated with a solution of Pd(PPh3)4 (1 equiv) and
427PhSiH3 (40 equiv) in dry CH2Cl2. The resin was shaken for 1 h and
428the procedure was repeated. Afterward, the resin was washed with
429CH2Cl2 (10 × 5 mL), DMF (5 × 5 mL), and CH2Cl2 (5 × 5 mL). A
430solution of ethyl-3-mercaptoproprionate (4 equiv) and PyBOP (4
431equiv) in DMF (2−3 mL) was added to the resin at −15 °C in a salt−
432ice−water bath. Subsequently, iPr2NEt (4 equiv) was added to the
433resin. The resin was left at −15 °C for 3 h. Afterward, the resin was
434washed with CH2Cl2 (10 × 5 mL), DMF (5 × 5 mL), and CH2Cl2 (5
435× 5 mL). The peptide was cleaved from resin and worked up as
436described in the general resin cleavage procedure. The dried pellet
437was dissolved in water containing 40% MeCN + 0.1% TFA, purified
438by preparative RP-HPLC (50−100% B over 40 min, 4 mL min−1, 40
439°C, Phenomenex Luna C18(2), 5 μm, 100 Å, 10 × 250 mm) and
440lyophilized to afford the desired lipopeptide thioester as a white solid
441(13.5 mg, 21% yield). Analytical HPLC: Rt 16.0 min (50−100% B
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442 over 30 min, 0.2 mL min−1, Phenomenex Luna C18(2), 5 μm, 2.1 ×
443 150 mm, λ = 214 nm). MS calcd: [M + 2H]2+ = 1300.24, [M + 3H]3+
444 = 867.17, [M + 4H]4+ = 650.62; found (ESI+): 1300.80, 867.45,
445 650.75.
446 Synthesis of Peptide 3. 2-Chlorotrityl chloride resin (50 μmol,
447 1.22 mmol/g loading) was swollen in dry CH2Cl2 for 30 min then
448 washed with CH2Cl2 (5 × 3 mL). A solution of Fmoc-Met-OH (0.5
449 equiv relative to resin functionalization) and iPr2NEt (2.0 equiv
450 relative to resin functionalization) in CH2Cl2 (final amino acid
451 concentration 0.1 M of amino acid) was added and the resin was
452 shaken at rt for 16 h. The resin was washed with DMF (5 × 3 mL)
453 and CH2Cl2 (5 × 3 mL). The resin was treated with a solution of
454 CH2Cl2/CH3OH/
iPr2NEt (17:2:1 v/v/v, 3 mL) for 1 h and washed
455 with DMF (5 × 3 mL), CH2Cl2 (5 × 3 mL), and DMF (5 × 3 mL).
456 The ESAT6(9−20)-TB10.4(3−11) peptide was synthesized via
457 Fmoc-strategy solid-phase peptide synthesis as outlined in the general
458 methods section. The peptide was cleaved from resin and worked up
459 via the general resin cleavage procedure. The dried pellet was
460 dissolved in water containing 30% MeCN + 0.1% TFA and purified by
461 preparative HPLC (0−60% B over 40 min, 7 mL min−1, Sunfire C18,
462 5 μm, 100 Å, 19 × 150 mm) to afford the desired peptide as a white
463 solid (35 mg, 32% yield). Analytical HPLC: Rt 13.1 min (0−100% B
464 over 30 min, 0.2 mL min−1, 0.1% TFA, Sunfire C18, 5 μm, 100 Å, 2.1
465 × 150 mm, λ = 214 nm). MS calcd: [M + 2H]2+ = 1102.50, [M +
466 3H]3+ = 735.33; found (ESI+): 1102.60, 734.45.
467 Fmoc-L-Asp-L-Phe-OAll (4). The protected dipeptide 8 (872 mg,
468 1.42 mmol) was treated with TFA in CH2Cl2 (10 mL, 1:1 v/v). The
469 reaction mixture was stirred at room temperature for 1 h, after which
470 the TFA/CH2Cl2 solvent mixture was removed under a gentle stream
471 of nitrogen. The residue was dissolved in CH2Cl2 and then washed
472 with water (2 × 30 mL), saturated aqueous NaHCO3 solution (2 ×
473 30 mL), and brine (30 mL). The organic phase was dried with
474 anhydrous MgSO4, concentrated in vacuo, and purified by flash
475 column chromatography to afford the target compound 4 as a yellow
476 oil (728 mg, 90% yield). Rf = 0.42 (EtOAc/hexane: 1:2 v/v)
1H NMR
477 (CDCl3, 400 MHz) δ (ppm): 7.77 (d, J = 7.41 Hz, 2H), 7.54 (m,
478 2H), 7.39 (t, J = 7.4 Hz, 2H), 7.29 (t, J = 7.4 Hz, 2H), 7.20−7.08 (m,
479 6H), 5.97 (d, 8.1 Hz, 1H), 5.82 (ddt, J = 5.5, 10.5, 16.5 Hz, 1H), 5.25
480 (dd, J = 17.9, 10.5 Hz, 2H), 4.85 (dd, 6.3, 6.8 Hz, 1H), 4.56 (m, 3H),
481 4.42−4.34 (m, 2H), 4.18 (t, J = 7.0 Hz, 1H), 3.12−3.06 (m, 3H),
482 2.70 (m, 1H); 13C NMR (CDCl3, 100 MHz) δ (ppm): 170.8, 156.1,
483 143.6, 141.3, 141.2, 135.5, 131.2, 129.2, 128.5, 128.5, 127.8, 127.2,
484 127.1, 125.1, 120.0, 119.1, 67.5, 66.2, 53.6, 50.7, 47.0, 37.7, 35.9;
485 HRMS: (+ESI) Calc. for 542.2053 [M + Na]+, found: 542.2058 [M +
486 Na]+; IR (ATR): vmax = 3300, 3065, 3030, 2924, 2854, 1710, 1661,
487 1532, 1449, 1248, 1211, 1049, 738, 701 cm−1; [α]D: +21° (c 1.0,
488 CH2Cl2).
489 Boc-L-Phe-OAll (6). Boc-L-Phe-OH 5 (799 mg, 3.0 mmol) was
490 dissolved in DMF (10 mL) and cooled to 0 °C in an ice bath. iPr2NEt
491 (1.57 mL, 9 mmol) was added dropwise, followed by allyl bromide
492 (280 μL, 3.3 mmol). The solution was allowed to warm to rt and
493 stirred for 16 h. The reaction mixture was diluted with EtOAc (40
494 mL), and then washed with water (2 × 30 mL) and brine (30 mL).
495 The organic phase was dried with anhydrous MgSO4, concentrated in
496 vacuo, and purified via flash column chromatography to afford allyl
497 ester 6 as a yellow oil (905 mg, 99% yield). 1H NMR (CDCl3, 400
498 MHz) δ (ppm): 7.33−7.13 (m, 5H), 5.88 (ddt, J = 5.7, 11.0, 16.2 Hz,
499 1H), 5.32 (dq, J = 2.0, 17.3 Hz, 1H), 5.26 (dd, J = 2.0, 10.5 Hz, 1H),
500 4.62 (dt, J = 1.5, 6.0 Hz, 2H), 3.18−3.05 (m, 2H), 1.44 (s, 9H). 13C
501 NMR (CDCl3, 100 MHz) δ (ppm): 171.6, 155.1, 135.9, 131.5, 129.4,
502 128.5, 127.2, 118.9, 79.9, 65.9, 54.5, 38.4, 28.3. These data are in
503 agreement with those previously reported by Lang et al.49
504 L-Phe-OAll (7). Boc-L-Phe-OAll (6) (885 mg, 2.90 mmol) was
505 treated with TFA in CH2Cl2 (10 mL, 1:1 v/v). The reaction mixture
506 was stirred at room temperature for 1 h, after which the TFA/CH2Cl2
507 solvent mixture was removed under a gentle stream of nitrogen. The
508 reaction mixture was diluted into CH2Cl2 (30 mL) and then washed
509 with water (2 × 30 mL) and brine (30 mL). The organic phase was
510 dried with anhydrous MgSO4 and then concentrated in vacuo to
511 afford 7 as a yellow oil (592 mg, 99% yield). 1H NMR (CDCl3, 400
512MHz) δ (ppm): 7.27−7.07 (m, 5H), 5.70 (ddt, J = 5.7, 11.0, 16.2 Hz,
5131H), 5.20−5.16 (m, 2H), 4.49 (d, J = 6.1 Hz, 2H), 4.20 (t, J = 7.0 Hz,
5141H), 3.24−3.11 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ (ppm):
515168.6, 132.9, 130.2, 129.3, 128.2, 120.2, 67.4, 54.3, 36.2. These data
516are in agreement with those previously reported by Lang et al.49
517Fmoc-L-Asp(OtBu)-L-Phe-OAll (8). A solution of Fmoc-L-Asp-
518(OtBu)-OH (1.21 g, 2.91 mmol), HATU (1.11 mg, 2.90 mmol), and
519N-methylmorpholine (NMM, 1 mL, 9.0 mmol) in DMF (final amino
520acid concentration 0.1 M) was added to a reaction vessel containing
521H-L-Phe-OAll 7 (533 mg, 2.6 mmol). The reaction was stirred for 2 h,
522after which the solvent was removed under a stream of nitrogen. The
523residue was dissolved into CH2Cl2 (30 mL), washed with water (2 ×
52430 mL), 2 M HCl (20 mL), saturated aqueous NaHCO3 solution (20
525mL), and brine (30 mL). The organic phase was dried with anhydrous
526MgSO4, concentrated in vacuo, and purified by flash column
527chromatography to afford the target compound S3 as a yellow oil
528(1.14 g, 74% yield); Rf = 0.40 (EtOAc/hexane, 3:7 v/v).
1H NMR
529(CDCl3, 300 MHz) δ (ppm): 7.72 (d, J = 7.9 Hz, 2H), 7.53 (d, J =
5307.5 Hz, 2H), 7.36 (dd, J = 7.1, 7.4 Hz, 2H), 7.30−6.96 (m, 7H), 5.90
531(d, J = 7.6 Hz, 1H), 5.79 (ddt, J = 6.0, 11.2, 16 Hz, 1H), 5.22 (dd, J =
53218, 10.6 Hz, 2H), 4.80 (dd, J = 13.1, 6.2 Hz, 1H), 4.50 (m, 1H),
5334.37−4.27 (m, 2H), 4.17 (dd, J = 14.1, 7.1 Hz, 1H), 3.07 (dd, J = 6.2,
5345.7 Hz, 2H), 2.84 (dd, 17, 4.0 Hz, 1H), 2.56 (dd, 17, 6.6 Hz, 1H),
5351.40 (s, 9H); 13C NMR (CDCl3, 75 MHz) δ (ppm): 171.2, 170.6,
536170.2, 155.9, 143.7, 141.3, 135.6, 131.4, 129.3, 128.5, 127.7, 127.1,
537125.1, 120.0, 119.0, 81.9, 67.3, 66.0, 53.6, 50.9, 47.0, 37.8, 28.5;
538HRMS: (+ESI) Calc. for 598.2679 [M + Na]+, found: 598.2681 [M +
539Na]+; IR (ATR): vmax = 3301, 3066, 3030, 2924, 2854, 1711, 1661,
5401532, 1449, 1248, 1211, 1050, 738, 701 cm−1; [α]D: +6.25° (c 1.0,
541CH2Cl2).
542In Vitro Assessment of Vaccine Adjuvant Activity. Human
543Embryonic Kidney 293 (HEK293; ATCC CRL-1573) cells, stably
544transfected with a plasmid expressing YFP-TLR2 fusion protein50 that
545secretes IL-8 upon TLR activation (kindly provided by A/Prof Ashley
546Mansell, Monash University), were used as a reporter of TLR2
547stimulation by Pam2Cys in the vaccine construct. Cells were grown in
548Dulbecco’s modified Eagle’s medium (Gibco, MA) with D-glucose
549(4.5 g/L), L-glutamine (3.996 mM), penicillin−streptomycin (100 U/
550mL; Gibco), geneticin (0.5 mg/mL; Gibco), and 10% heat-inactivated
551fetal calf serum (FCS) at 37 °C and 5% CO2. After seeding 2 × 105
552cells/well of a 96-well flat-bottom plate (Corning) and allowing cells
553to adhere, the cells were stimulated in triplicate for 16−18 h with
554vaccine candidate 1 (33.5 μg/mL; such that Pam2Cys-SKKKK-
555triethyleneglycolate was at 10 μg/mL, the optimal concentration for
556stimulation of this cell line as determined by previous experiments,
557ESAT61−20 ∼15 μg/mL and TB10.43−11 ∼8 μg/mL). As a
558comparison, Pam2Cys-SKKKK-triethyleneglycolate (10 μg/mL),
559ESAT61−20 peptide (15 μg/mL), or TB10.43−11 peptide (Genscript;
5608 μg/mL) was also used as a stimulus. Supernatants were collected
561and IL-8 secretion determined as a measure of stimulation of TLR2
562by ELISA (Biolegend), according to manufacturer’s instructions. Data
563shown are representative of two independent experiments.
564Mice and Immunization Procedures. All murine experiments
565were conducted with the approval of the Sydney Local Health District
566Animal Welfare Committee (protocol numbers 2013/054, 2013/075,
567and 2016/044), in full compliance with local and institutional
568guidelines. Female C57BL/6 6- to 8-week old mice were obtained
569from Animal BioResources (Moss Vale, NSW, Australia). The mice
570were housed in the Centenary Institute animal facility under SPF
571conditions. For i.n. administration, mice were anesthetized by
572intraperitoneal injection of ketamine/xylazine solution (50 mg/6.25
573mg/kg). Vaccine (14.2 μg, equivalent to 10 μg peptide) in phosphate-
574buffered saline (PBS; 50 μL final volume, such that the vaccine
575reached the deep lung) was applied to the nares and mice allowed to
576inhale the solution. Mice receiving subcutaneous vaccines (14.2 μg for
577protection studies and 56.8 μg for immunogenicity studies, equivalent
578to 10 or 40 μg peptide respectively; in PBS, 200 μL final volume)
579were anesthetized with gaseous isoflurane (4%) and injected at the
580base of tail. No adverse effects were observed in mice receiving this
581vaccine by either mucosal or subcutaneous routes. Mice received 3
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582 vaccinations 2 weeks apart and proceeded to either immunogenicity
583 study at 3 weeks after last vaccination, or Mtb challenge at 6 weeks
584 after last vaccination. Mice receiving BCG were vaccinated s.c. once
585 only with 5 × 105 CFU, 10 weeks prior to Mtb challenge.
586 Bacterial Strains and Growth Conditions. Mangora bovis BCG
587 Pasteur 1173P2 and Mtb H37Rv (BEI Resources, NIAID, NIH, NR-
588 13648) were cultured at 37 °C in Middlebrook 7H9 (Difco) broth
589 supplemented with albumin-dextrose-catalase (ADC; 10% v/v),
590 Tween-80 (0.05% v/v), and glycerol (0.2% v/v). To enumerate,
591 cultures were plated onto Middlebrook 7H10 or 7H11 (Difco) agar,
592 supplemented with oleic-acid-albumin-dextrose catalase (10% v/v)
593 and glycerol (0.5% v/v) and incubated at 37 °C for up to 21 days.
594 Experimental Mtb Infection. At 6 weeks after 3 immunizations,
595 mice received a low-dose aerosol infection (100 CFU) in an
596 inhalation exposure system (Glas-Col, Terre Haute, IN). At 4
597 weeks after challenge, serial dilutions of lung and spleen homogenates
598 were plated to enumerate the bacterial loads.
599 Collection and Processing of Murine Organs for Leukocyte
600 Isolation. Mice were sacrificed via CO2 asphyxiation, the tissues
601 removed aseptically and maintained at 4 °C. Circulating blood was
602 removed from the lung lobes by perfusion with an injection of PBS
603 and heparin (20 U/mL; Sigma) into the right atrium of the heart. For
604 isolation of leukocytes, diced tissue was digested with collagenase type
605 4197 (50 U/mL; Sigma) and DNAse I (13 μg/mL; Sigma) at 37 °C
606 for 45 min, followed by homogenization and multiple filtration steps
607 through a 70 μm sieve. The spleen, mediastinal lymph node (MLN)
608 of i.n. immunized mice or inguinal lymph nodes (ILN) of s.c.
609 immunized mice was homogenized through a 70 μm sieve and the
610 leukocytes pelleted by centrifugation. Erythrocytes were removed by
611 ACK lysis buffer, then viable leukocytes enumerated by hemocy-
612 tometer or using a BD Countess, with Trypan Blue (0.04%) exclusion.
613 Polyfunctional T-Lymphocyte Responses to Immunization.
614 Epitope-specific cytokine production by T-lymphocytes was enum-
615 erated by antigen-recall, intracellular immunostaining, and flow
616 cytometry. Single-cell suspensions of up to 4 × 106 lymphocytes
617 were stimulated for 1−2 h (37 °C, 5% CO2) with ESAT61−20 or
618 TB10.43−11 peptides (10 μg/mL; Genscript), or with antimouse CD3
619 (1452C11, 5 μg/mL) and antimouse CD28 (37.51, 5 μg/mL; BD
620 Pharmingen) or media alone as controls. Brefeldin A (10 μg/mL;
621 Sigma) was added and further incubation (16 h, 37 °C, 5% CO2)
622 allowed intracellular accumulation of cytokine. After washing with
623 FACS wash (PBS with 2% FCS), Fc receptors were blocked with
624 antimouse CD16/CD32 (2.4G2; BD Biosciences). Surface markers
625 were labeled with an antimouse CD8-APCCy7 (53-6.7; BD
626 Pharmingen, San Jose, CA), CD4-PECy7 (RM4-5; BD Pharmingen),
627 CD3-PerCPCy5.5 (17A2; Biolegend, San Diego, CA), and Live/Dead
628 fixable blue dead cell stain (Invitrogen, CA) in FACS wash, then the
629 cells were washed thoroughly. Cells were fixed using BD Cytofix/
630 perm, followed by thorough washing with BD Perm/Wash. To label
631 intracellular cytokines, cells were incubated with antimouse IFNγ-
632 FITC (XMG1.2; BD Pharmingen), IL-17A-PB (TC11-18H10.1;
633 Biolegend), TNFα-PE/APC (MP6-XT22; Biolegend), and IL-2-
634 APC/PE (JES6-5H4; Biolegend) prepared in BD Perm/Wash buffer
635 and then washed. Compensation controls were prepared by
636 immunostaining BD CompBeads with the same antibody utilized in
637 the experimental panel, except for live dead staining, in which case
638 murine leukocytes were labeled in the same manner as experimental
639 samples. Immunostained cells or beads were fixed in 10% neutral
640 buffered formalin prior to the acquisition of the data using an
641 LSRFortessa or LSRII 5L flow analyser (BD Biosciences) and analysis
642 using FlowJo (Tree Star Inc.).
643 Statistical Analysis. Statistical analysis was performed using
644 GraphPad Prism 6 or 7 software (GraphPad Software, La Jolla, CA),
645 as detailed in figure legends. Differences between two groups were
646 analyzed by Students t-test, or between multiple groups by one- or
647 two-way analysis of variance (ANOVA) with Tukey’s or Dunnett’s
648 multiple comparisons test and were considered significant when p
649 values were ≤ 0.05 (*p < 0.05, **p < 0.01, ***p < 0.001, ****p <
650 0.0001).
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